More articles about Diagnostics

The molecular diagnostics firm grew year-over-year testing volumes by 28 percent to 167,172.

The company beat Wall Street estimates, and officials said momentum is building as the firm readies its GeoMx digital spatial profiling technology for launch.

The company said testing services revenues more than doubled during the quarter as its AlloSure kidney transplant diagnostic continued to penetrate the market.

The firm will use the funding to advance commercialization of its RNA disruption assay and continue its breast cancer response therapy trial.

The firm signed four new distribution deals to spread its products into more than a dozen new markets.

The firm sees the Phenoptics system as a highly automated, high-throughput imaging platform that can be used to translate discoveries made on its CODEX device.

The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.

At a Thermo Fisher-sponsored workshop, two companies argued for the clinical utility of PGx LDTs as FDA prepared to issue a warning against unapproved tests.

Researchers separately found that the assay had high concordance with other techniques in cancers including colorectal and endometrial carcinomas.

The companies plan to study the current utility and understanding of NGS and precision medicine, and will provide educational programs in underserved areas.

The company accessioned approximately 78,000 samples in Q3 2018, up 95 percent from the year-ago quarter when it accessioned 40,000 samples..

MDx revenues increased 3 percent to $158.0 million, but excluding non-recurring royalty revenue in the prior-year period, MDx revenues increased 10 percent.

Researchers found that combining tumor and cancer cell line data with their MAGNETIC analysis approach could enhance drug response predictions.

The German molecular diagnostics firm recently completed a capital increase with subscription rights for existing shareholders, grossing €22.3 million.

The genetic testing firm said the revenue growth was driven by a 37 percent increase in the number of billable tests delivered in the quarter.

The company attributed the growth to increasing global demand for breast cancer testing, and growing demand and reimbursement for its prostate test.

The firm saw 60 percent revenue growth in molecular diagnostics, including 88 percent growth in its Solana system.

Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.

Stratec is producing the microfluidic chips for Vortex' VTX-1 system, which enables the enrichment and isolation of circulating tumor cells.

The firm's full fiscal year revenues were also up, 32 percent as reported, or about 6 percent on a currency-neutral basis.

Pages

Though many details have yet to be worked out, the draft deal for the UK's withdrawal from the EU is giving researchers some hints for what they can expect, Nature News says.

DNA testing has solved a 100-year-old mystery contained in the skull and teeth samples of a now-extinct monkey that once inhabited Jamaica, Gizmodo reports.

As the UN ponders a ban on gene drives, one malaria researcher says there are less dramatic ways to fight the disease in Africa than unleashing GM mosquitoes on a whole continent.

In Nature this week: an improved reference genome of the Aedes aegypti mosquito, genomes of four species of truffles, and more.